Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
äŒæ¥ã³ãŒãDNA
äŒç€ŸåGinkgo Bioworks Holdings Inc
äžå Žæ¥Apr 19, 2021
æé«çµå¶è²¬ä»»è
ãCEOãKelly (Jason)
åŸæ¥å¡æ°834
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Apr 19
æ¬ç€Ÿæåšå°27 Drydock Avenue
éœåžBOSTON
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœUnited States of America
éµäŸ¿çªå·02210
é»è©±çªå·18774425362
ãŠã§ããµã€ãhttps://investors.ginkgobioworks.com/
äŒæ¥ã³ãŒãDNA
äžå Žæ¥Apr 19, 2021
æé«çµå¶è²¬ä»»è
ãCEOãKelly (Jason)